Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) is a T-cell costimulatory receptor. GITR agonists have been shown to stimulate antitumor immunity in preclinical models. This Phase I study of MEDI1873, a novel GITR ligand/immunoglobulin 1 (IgG1) agonist fusion protein, demonstrated engagement of GITR on circulating memory T cells, thereby enhancing effector T cell function through inducing peripheral IFNγ, IP-10, I-TAC, and MIG, and increasing circulating Ki67+ CD4+ cells in patients with advanced solid tumors. MEDI1873 also reduced intratumoral GITR+ FoxP3+ cells. Several patients had prolonged stable disease, exceeding 1 year in two cases. Although some findings were encouraging, there are no plans for further clinical exploration of MEDI1873.Research.

No abstract

The amplitude of resorption of the diced cartilage wrapped in fascia is considerable compared with one-piece block grafts. It may be anticipated that the enthusiasm for this technique will decline once the long-term results of pertaining clinical studies are available.

<p>Supplementary Table 1. Characteristics of patients with prolonged SD ({greater than or equal to}24 weeks)</p>

<p>Patients receiving MEDI1873 at doses ranging from 7.5-25 mg or 75-250 mg were assessed for changes in the soluble factors interferon gamma (IFNy), IFNy-induced protein 10 (IP-10), interferon-inducible T cell alpha chemoattractant(I-TAC), and monokine induced by IFNy (MIG).</p>

<p>Visits after Day 57 were excluded for visual purposes. The excluded visits were: Days 71, 85, 99, 127, 155, 183, 211, 239, 267, 295, 323 and 351.</p>

<p>(A) Changes from baseline were measured in peripheral CD4+ Ki67+ T cells in the 25 mg, 75 mg, 250 mg, and 500 mg cohorts. (B) The associations between peripheral IFNy and GITR. GITR molecule equivalents of soluble fluorescence (MESF) were assessed.</p>

<p>Visits after Day 57 were excluded for visual purposes. The excluded visits were: Days 71, 85, 99, 127, 155, 183, 211, 239, 267, 295, 323 and 351.</p>